CN111235035A - Schizochytrium limacinum mutant strain, and method and application thereof in preparation of docosahexaenoic acid grease - Google Patents

Schizochytrium limacinum mutant strain, and method and application thereof in preparation of docosahexaenoic acid grease Download PDF

Info

Publication number
CN111235035A
CN111235035A CN201911399018.2A CN201911399018A CN111235035A CN 111235035 A CN111235035 A CN 111235035A CN 201911399018 A CN201911399018 A CN 201911399018A CN 111235035 A CN111235035 A CN 111235035A
Authority
CN
China
Prior art keywords
docosahexaenoic acid
culture
content
schizochytrium
mutant strain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201911399018.2A
Other languages
Chinese (zh)
Inventor
汪志明
陆姝欢
余超
李慕梓
杨艳红
李翔宇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cabio Biotech Wuhan Co Ltd
Original Assignee
Cabio Biotech Wuhan Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cabio Biotech Wuhan Co Ltd filed Critical Cabio Biotech Wuhan Co Ltd
Priority to CN201911399018.2A priority Critical patent/CN111235035A/en
Publication of CN111235035A publication Critical patent/CN111235035A/en
Pending legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14Fungi; Culture media therefor
    • C12N1/145Fungal isolates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12RINDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00Microorganisms ; Processes using microorganisms
    • C12R2001/645Fungi ; Processes using fungi
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14Fungi; Culture media therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00Preparation of oxygen-containing organic compounds
    • C12P7/64Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6436Fatty acid esters
    • C12P7/6445Glycerides
    • C12P7/6463Glycerides obtained from glyceride producing microorganisms, e.g. single cell oil
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00Preparation of oxygen-containing organic compounds
    • C12P7/64Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6436Fatty acid esters
    • C12P7/6445Glycerides
    • C12P7/6472Glycerides containing polyunsaturated fatty acid [PUFA] residues, i.e. having two or more double bonds in their backbone

Abstract

The invention relates to a schizochytrium limacinum mutant strain, a method for preparing docosahexaenoic acid grease by using the same and application thereof, wherein the strain is preserved in a China center for type culture collection (CCTCCM 2019990) 12, 2 and 2019 at the preservation address of Wuhan university in Wuhan city, Hubei province, China. According to the invention, the schizochytrium limacinum mutant strain CCTCCM2019990 is obtained by screening through high-throughput culture and the sedimentation characteristic of the schizochytrium limacinum by combining ultraviolet mutagenesis with an ion beam mutagenesis technology, and the mutant strain is used for producing docosahexaenoic acid grease, so that the obtained docosahexaenoic acid grease is low in long-chain saturated fatty acid content, the lowest content of C18:0 is 0.4 wt%, the lowest content of C16:0 is 12.5 wt%, and the highest content of DHA can reach 57.08 wt%, and the intake of diabetes mellitus crowds is facilitated.

Description

Schizochytrium limacinum mutant strain, and method and application thereof in preparation of docosahexaenoic acid grease
Technical Field
The invention relates to the field of microorganisms, in particular to a schizochytrium limacinum mutant strain and a method and application thereof for preparing docosahexaenoic acid grease.
Background
Diabetes is a group of metabolic diseases characterized by hyperglycemia. Hyperglycemia occurring in diabetes over a long period of time can lead to chronic damage to, and dysfunction of, various tissues, particularly the eyes, kidneys, heart, blood vessels, nerves. The prevalence of diabetes is higher in the elderly, men, urban residents, residents in economically developed areas, overweight and obese people.
Diabetes mellitus is divided into type 1 diabetes mellitus and type 2 diabetes mellitus, insulin resistance is one of the main pathophysiological characteristics of type 2 diabetes mellitus, and numerous researches show that n-3 polyunsaturated fatty acid including DHA can regulate immunity and reduce the release of inflammatory factors through various molecular mechanisms, so that the lipid metabolism of type 2 diabetes mellitus is improved, the insulin sensitivity is improved, and diabetes mellitus and complications are favorably prevented and treated.
At present, the main source of DHA is oil produced by marine microorganisms, and the related marine microorganisms comprise thraustochytrium, schizochytrium and the like. Microbial oils contain, in addition to polyunsaturated fatty acids, a significant amount of long chain saturated fatty acids, especially palmitic acid C16:0, typically in amounts of greater than 2 wt%, and in certain microbial oils C16:0 up to 50 wt%. There is evidence that excessive intake of long chain saturated fatty acids can cause lipid accumulation in the body to cause lipotoxicity, resulting in insulin resistance in skeletal muscle, adipose tissue and liver. In addition, studies have been made to restore insulin sensitivity by knocking out mouse long chain fatty acid elongase 6, which causes the proportion and change of fatty acid composition, indicating that long chain fatty acid elongase may be a potential target for the treatment of insulin resistance, diabetes, cardiovascular diseases and other metabolic diseases. These studies suggest that both endogenous and exogenous long chain fatty acids negatively impact type 2 diabetes.
Because the diabetes risk people have a high-oil dietary habit, the people who take DHA and reduce the intake of long-chain saturated fatty acid become urgent needs of the people, and the high-content DHA grease can reduce C16 as far as possible under the condition of meeting the normal intake of DHA: 0 and other long chain saturated fatty acids. Therefore, the development of a DHA microbial oil rich in DHA and low in long-chain saturated fatty acid, especially C16:0 palmitic acid, is urgently needed.
Disclosure of Invention
In order to solve the problems, the invention provides a schizochytrium limacinum mutant strain, and a method and application thereof for preparing docosahexaenoic acid grease.
In A first aspect, the present invention provides A Schizochytrium sp CABIO-A-2-II strain, which has the following deposit information: the preservation number is CCTCCM 2019990; the classification is named as: schizochytrium sp; the preservation unit is China center for type culture Collection; the preservation address of Wuhan university in Wuhan city, Hubei province, China, the zip code: 430072; the preservation date is 12 months and 2 days in 2019.
The invention adopts ultraviolet mutagenesis combined with ion beam mutagenesis technology, obtains A schizochytrium mutant strain through high-throughput culture and the sedimentation characteristic of the schizochytrium, and determines that the schizochytrium mutant strain CABIO-A-2-II accords with the characteristic of the schizochytrium through culture characteristic, micro morphological characteristic, physiological and biochemical characteristic and genetic characteristic.
The physiological characteristics of the schizochytrium limacinum mutant strain CABIO-A-2-II provided by the invention are as follows:
(1) the vegetative cells are single cells, are nearly spherical, have the diameter of 4-11 mu m, and are proliferated in a typical binary division mode;
(2) in liquid culture, the cells generally aggregate into large aggregates;
(3) the optimum culture temperature is 25 ℃.
The invention further provides A microbial inoculum containing the Schizochytrium limacinum mutant strain CABIO-A-2-II.
In A second aspect, the invention provides A method for producing docosahexaenoic acid grease by using the schizochytrium limacinum mutant strain CABIO-A-2-II or microbial inoculum, which comprises the following steps: fermenting the Schizochytrium limacinum mutant strain CABIO-A-2-II or microbial inoculum, collecting fermentation product, and separating and purifying.
As A preferred embodiment, the invention provides A method for producing docosahexaenoic acid grease by using the Schizochytrium limacinum mutant strain CABIO-A-2-II or microbial inoculum, which comprises the following specific steps:
(1) activating and culturing seeds: inoculating the Schizochytrium limacinum mutant strain CABIO-A-2-II or the microbial inoculum into an activation culture medium, and performing shake culture to obtain A seed activation culture solution;
(2) seed amplification culture: inoculating the seed culture solution cultured by shaking in the step (1) into an amplification culture medium for shaking culture to obtain a seed amplification culture solution;
(3) fermentation culture: inoculating the seed culture solution cultured by shaking in the step (2) into a fermentation bottle filled with a fermentation culture medium for fermentation culture;
or according to the size of the final fermentation tank, carrying out amplification culture on the seed culture solution cultured in the shake flask in the step (2) step by step to obtain a seed amplification culture solution, and then inoculating the seed amplification culture solution into the fermentation tank for fermentation culture.
(4) And (3) carrying out post-treatment on the fermentation liquor to obtain the docosahexaenoic acid grease.
Further, the step (1) is as follows: inoculating the Schizochytrium limacinum mutant strain CABIO-A-2-II into an activation culture medium for culturing at the temperature of 25-30 ℃, with the shaking table shaking rotation speed of 150-: 10-20g/L of glucose, 20-30g/L of sodium glutamate, 5-10g/L of yeast extract, 10-20g/L of sodium chloride, 0.5-1g/L of magnesium sulfate and natural pH.
Further, the step (2) is as follows: when the bacterial concentration of the seed activation culture solution in the step (1) reaches 3-6% (volume concentration), inoculating the seed activation culture solution into an amplification culture medium according to the inoculation amount of 5-20% (volume ratio) for culture, wherein the culture temperature is 25-30 ℃, the culture time is 32-48h, the shaking table shaking rotation speed is 150-: 30-50g/L of glucose, 20-40g/L of sodium glutamate, 5-10g/L of yeast extract, 10-20g/L of sodium chloride, 5-10g/L of magnesium sulfate, 5-10g/L of monopotassium phosphate, 0.5-1g/L of calcium chloride and natural pH.
Further, the step (3) may also be: and (3) carrying out stepwise amplification culture on the seed culture solution cultured in the shake flask in the step (2) according to the size of a final fermentation tank to obtain the seed amplification culture solution, inoculating the seed amplification culture solution into the fermentation tank for fermentation culture when the bacteria concentration of the seed amplification culture solution reaches 3-6% (volume concentration), wherein the inoculation amount is 10-20% (volume ratio), the temperature of the fermentation tank is 25-30 ℃, the stirring speed is 100-250 r/min, the ventilation amount is 0.5-2vvm (L/L.min), namely the required air introduction amount per minute in each liter of fermentation liquor is 1-2L, the tank pressure is 0.05-0.1MPa, and the culture is carried out for 96-120h, wherein the fermentation culture medium in the fermentation tank is: 40-60g/L of glucose, 4-6g/L of yeast extract, 20-40g/L of sodium glutamate, 1-5g/L of sodium chloride, 1-5g/L of monopotassium phosphate, 5-10g/L of magnesium sulfate, 0.5-1g/L of calcium chloride, 0.5-1g/L of sodium bicarbonate, 5-10g/L of sodium sulfate, 5-20g/L of ammonium sulfate, 0.5-1g/L of potassium chloride and natural pH.
In a more preferred embodiment, the concentration of the carbon source in the fermentation broth in step (3) can be controlled to be 5 to 20g/L by feeding glucose during the fermentation.
In a more preferred embodiment, the pH of the fermentation broth in step (3) can be controlled between 6 and 8 by adding citric acid or hydrochloric acid during the fermentation.
Further, the post-treatment in the step (4) is to perform wall breaking on thalli in the fermentation liquor by using alkaline protease, and then adding an extracting agent for extraction.
The bacterial concentration is the proportion of the volume of the lower layer of bacteria in the total system volume after the culture solution is centrifuged.
The docosahexaenoic acid oil obtained by the method contains C16:0 less than 15.50%, long-chain saturated fatty acid C16:0 and C18:0 less than 16.01 wt%, and DHA higher than 50.40%.
In A third aspect, the invention provides the application of the schizochytrium limacinum mutant strain CABIO-A-2-II and A microbial inoculum in preparation of docosahexaenoic acid grease.
Further, the content of C16:0 in the docosahexaenoic acid oil is less than 15.50 wt%, preferably less than 15.00 wt%, more preferably less than 14.12 wt%, and still more preferably less than 12.50 wt%.
Further, the content of C18:0 in the docosahexaenoic acid oil is less than 0.51 wt%, preferably less than 0.41 wt%, and more preferably less than 0.40 wt%.
Further, the sum of the contents of long-chain saturated fatty acids C16:0 and C18:0 in the docosahexaenoic acid oil is less than 16.01 wt%, preferably less than 15.41 wt%, more preferably less than 14.52 wt%, and even more preferably less than 12.90 wt%.
Furthermore, the DHA content of the docosahexaenoic acid grease is higher than 50.40 wt%, preferably higher than 52.37 wt%, further preferably higher than 54.90 wt%, and further preferably higher than 57.08 wt%.
The invention further provides the application of the schizochytrium limacinum mutant strain CABIO-A-2-II, the microbial inoculum and the docosahexaenoic acid grease in preparing food, feed, cosmetics or medicines.
The invention further provides a microbial oil, wherein the content of docosahexaenoic acid oil in the microbial oil is at least 50%, and the content of long-chain saturated fatty acid C16:0 in the docosahexaenoic acid oil is less than 15.50 wt%, preferably less than 15.00 wt%, further preferably less than 14.12 wt%, and further preferably less than 12.50 wt%.
The invention provides a schizochytrium limacinum mutant strain, a method for preparing docosahexaenoic acid grease by using the same and application thereof, and the schizochytrium limacinum mutant strain has the following beneficial effects:
the invention adopts ultraviolet mutagenesis combined with ion beam mutagenesis technology, obtains A schizochytrium mutant strain CABIO-A-2-II by screening through high-throughput culture and the sedimentation characteristic of the schizochytrium, and utilizes the mutant strain to produce the long-chain saturated fatty acid C16 in the docosahexaenoic acid grease: 0 and C18: the content of 0 is less than 16.01 wt%, and is stable and appropriate with the fermentation state, further, less than 15.41 wt%, also less than 14.52 wt%, and as low as 12.90 wt%, and the content of DHA is at least higher than 50.40 wt%, and as high as 57.08 wt%. The invention has the advantages that the microbial oil produced by the mutant strain has low content of long-chain saturated fatty acid, and is more beneficial to the intake of diabetes patients.
Drawings
FIG. 1 is A diagram showing the results of microscopic observation of the growth and propagation process of Schizochytrium sp CABIO-A-2-II according to example 1 of the present invention.
Detailed Description
The following examples are intended to illustrate the invention but are not intended to limit the scope of the invention.
Example 1 Breeding of Schizochytrium limacinum mutant strains
The embodiment provides a method for breeding schizochytrium limacinum mutant strains, which comprises the following specific steps:
(1) schizochytrium limacinum obtained by screening and separating from seawater is used as an original strain, and the strain is obtained from a yellow sea water area of Shandong province.
(2) Inoculating the strain to an activation culture medium for culturing at 28 ℃ at the shaking table rotation speed of 200r/min for 48h to logarithmic phase.
(3) And (3) injecting 1ml of the activated seed culture solution obtained in the step (2) onto a sterile culture dish, and irradiating by using an ultraviolet lamp, wherein the irradiation distance of the ultraviolet lamp is 30 cm, the irradiation time is 60 seconds, and the power of the ultraviolet lamp is 30 watts.
(4) The bacteria liquid after ultraviolet mutagenesis is dried by sterile wind to become bacterial plaque. Aseptically transferring the culture dish containing bacterial plaque into high-energy particle beam injection machine, and allowing the culture dish to pass through high-energy N with energy of 20KeV+Ion beam implantation mutagenesis, N+The ion beam implantation dosage is 100 x 1017ions/cm2
(5) And (3) eluting the mycoderm subjected to mutagenesis treatment by using sterile water, diluting, coating on an activation medium flat plate for culturing, wherein the solid activation medium is as follows: 10g/L of glucose, 25g/L of sodium glutamate, 10g/L of yeast extract, 20g/L of sodium chloride, 0.5g/L of magnesium sulfate, 20g/L of agar powder and natural pH. Collecting the mutagenized single colony, inoculating the single colony into a porous plate filled with a fermentation culture medium by using a toothpick point for culturing at the culture temperature of 28 ℃ and the shaking speed of a shaking table of 200r/min for 96 h; transferring the fermentation liquor in the porous plate into a glass test tube, standing and settling, and observing the layering condition; selecting single colony fermentation liquor with slow cell sedimentation for detection and analysis; and (3) carrying out vacuum drying on the screened cells, taking a 20mg sample for fatty acid component analysis, and taking a single colony with the long-chain saturated fatty acid content of less than 20 wt% and the DHA content of more than 35 wt% in the fatty acid component as a starting strain for next step of mutagenesis. The fermentation medium is as follows: 40-60g/L of glucose, 4-6g/L of yeast extract, 20-40g/L of sodium glutamate, 1-5g/L of sodium chloride, 1-5g/L of monopotassium phosphate, 5-10g/L of magnesium sulfate, 0.5-1g/L of calcium chloride, 0.5-1g/L of sodium bicarbonate, 5-10g/L of sodium sulfate, 5-20g/L of ammonium sulfate, 0.5-1g/L of potassium chloride and natural pH.
In the embodiment, A mutant strain with low content of long-chain saturated fatty acid is obtained through multiple mutagenesis and screening, the strain is subjected to continuous subculture for 10 times, the lowest content of palmitic acid C16:0 can reach 12.50 wt%, the lowest content of stearic acid C18:0 can reach 0.40 wt%, and the highest content of DHA can reach 56.68 wt%, the mutant strain is the Schizochytrium mutant strain (Schizochytrium sp.) CABIO-A-2-II, and the strain is stored in the ChinA center for type culture collection in 12 months and 2 days in 2019; the preservation address is Wuhan university in Wuhan city of Hubei province in China; and E, postcode: 430072, with a collection number of CCTCCM2019990, and is classified and named as: schizochytrium sp.
The schizochytrium limacinum strain CABIO-A-2-II has the following characteristics:
(1) the vegetative cells are unicellular, nearly spherical, and have a diameter of 4-11 μm, and are proliferated in a typical binary division manner, and the growth state under a microscope is shown in figure 1;
(2) in liquid culture, the cells generally aggregate into large aggregates;
(3) the optimum culture temperature is 25 ℃.
Example 2 production of docosahexaenoic acid Using Schizochytrium limacinum mutant strains
In this example, the starting strain obtained by screening and separating in step (1) of example 1 was used to produce docosahexaenoic acid by the following specific method:
(1) activating and culturing seeds: inoculating the starting strain into an activation culture medium for culturing at the culture temperature of 28 ℃, the shaking rotation speed of a shaking table of 200r/min for 48h, wherein the activation culture medium is as follows: 10g/L of glucose, 25g/L of sodium glutamate, 10g/L of yeast extract, 20g/L of sodium chloride, 0.5g/L of magnesium sulfate and natural pH.
(2) Seed amplification culture: inoculating the activated seed culture solution cultured by shaking in the step (1) into an amplification culture medium according to the inoculation amount of 10% (volume ratio) for culturing, wherein the culture temperature is 28 ℃, the culture time is 48h, the shaking rotation speed of the shaking table is 200r/min, and the amplification culture medium in the shaking table is as follows: 40g/L glucose, 25g/L sodium glutamate, 10g/L yeast extract, 10g/L sodium chloride, 5g/L magnesium sulfate, 1g/L potassium dihydrogen phosphate, 0.5g/L calcium chloride and natural pH.
(3) And (3) fermentation bottle culture: inoculating the expanded seed culture solution cultured by shaking in the step (2) into a fermentation bottle filled with a fermentation culture medium according to the inoculation amount of 10% (volume ratio), and carrying out fermentation culture at the culture temperature of 28 ℃ for 120h at the shaking rotation speed of 220 r/min, wherein the fermentation culture medium is: 40g/L glucose, 4g/L yeast extract, 30g/L sodium glutamate, 5g/L sodium chloride, 1g/L monopotassium phosphate, 5g/L magnesium sulfate, 0.5g/L calcium chloride, 0.5g/L sodium bicarbonate, 8g/L sodium sulfate, 6g/L ammonium sulfate, 0.5g/L potassium chloride and natural pH.
(4) And (3) post-treatment: and (2) breaking the wall of fermentation liquor obtained by fermentation culture with alkaline protease, adding an extracting agent n-hexane for extraction, transferring a solid phase obtained by separation after extraction into an extraction container for repeated extraction, ending the extraction process until no oil exists in the extraction liquor, adding 200 ml of n-hexane during the first extraction, adding 150 ml of n-hexane each time, filtering and separating mixed oil after each extraction, and desolventizing to obtain the microbial oil.
(5) Gas chromatographic analysis: performing gas chromatography analysis on the microbial oil obtained in the step (4) to obtain the results shown in the table 1:
TABLE 1 DHA oil and fat obtained in comparative example 2
Fatty acid composition Content (wt%)
14:0 5.37%
16:0 28.50%
18:0 0.91%
18:1 0.40%
18:2 0.91%
20:4n6 2.50%
20:5n3(EPA) 1.79%
22:5n6 17.36%
22:5n3 1.30%
22:6n3(DHA) 39.90%
In the DHA oil prepared by the starting strain in this example, the content of palmitic acid C16:0 was 28.50 wt%, the content of stearic acid C18:0 was 0.91 wt%, the content of long chain fatty acid was 29.41 wt%, and the content of DHA was 39.9 wt%.
Example 3 production of docosahexaenoic acid Using Schizochytrium limacinum mutant strains
In this example, the method for producing docosahexaenoic acid by using the schizochytrium limacinum mutant obtained in example 1 is as follows:
(1) activating and culturing seeds: the schizochytrium limacinum mutant strain CABIO-A-2-II in example 1 is inoculated into an activation culture medium for culturing, the culture temperature is 28 ℃, the shaking table shaking speed is 200r/min, and the culture time is 48h, wherein the activation culture medium is as follows: 10g/L of glucose, 25g/L of sodium glutamate, 10g/L of yeast extract, 20g/L of sodium chloride, 0.5g/L of magnesium sulfate and natural pH.
(2) Seed amplification culture: inoculating the activated seed culture solution cultured by shaking in the step (1) into an amplification culture medium according to the inoculation amount of 10% (volume ratio) for culturing, wherein the culture temperature is 28 ℃, the culture time is 48h, the shaking rotation speed of the shaking table is 200r/min, and the amplification culture medium in the shaking table is as follows: 40g/L glucose, 25g/L sodium glutamate, 10g/L yeast extract, 10g/L sodium chloride, 5g/L magnesium sulfate, 1g/L potassium dihydrogen phosphate, 0.5g/L calcium chloride and natural pH.
(3) And (3) fermentation bottle culture: inoculating the expanded seed culture solution cultured by shaking in the step (2) into a fermentation bottle filled with a fermentation culture medium according to the inoculation amount of 10% (volume ratio), and carrying out fermentation culture at the culture temperature of 28 ℃ for 120h at the shaking rotation speed of 220 r/min, wherein the fermentation culture medium is: 40g/L glucose, 4g/L yeast extract, 30g/L sodium glutamate, 5g/L sodium chloride, 1g/L monopotassium phosphate, 5g/L magnesium sulfate, 0.5g/L calcium chloride, 0.5g/L sodium bicarbonate, 8g/L sodium sulfate, 6g/L ammonium sulfate, 0.5g/L potassium chloride and natural pH.
(4) And (3) post-treatment: and (2) breaking the wall of fermentation liquor obtained by fermentation culture with alkaline protease, adding an extracting agent n-hexane for extraction, transferring a solid phase obtained by separation after extraction into an extraction container for repeated extraction, ending the extraction process until no oil exists in the extraction liquor, adding 200 ml of n-hexane during the first extraction, adding 150 ml of n-hexane each time, filtering and separating mixed oil after each extraction, and desolventizing to obtain the microbial oil.
(5) Gas chromatographic analysis: performing gas chromatography analysis on the microbial oil obtained in the step (4) to obtain the results shown in the table 2:
table 2 content of each fatty acid in DHA oil in example 3
Figure BDA0002347036640000091
Figure BDA0002347036640000101
In the DHA grease prepared by the mutant strain in the embodiment, the content of palmitic acid C16:0 is 15.5 wt%, the content of stearic acid C18:0 is 0.51 wt%, and the content of DHA reaches 50.4 wt%.
Example 4 production of docosahexaenoic acid Using Schizochytrium limacinum mutant strains
In this example, the method for producing docosahexaenoic acid by using the schizochytrium limacinum mutant obtained in example 1 is as follows:
(1) activating and culturing seeds: the schizochytrium limacinum mutant strain CABIO-A-2-II in example 1 is inoculated into an activation culture medium for culturing, the culture temperature is 28 ℃, the shaking table shaking speed is 200r/min, and the culture time is 48h, wherein the activation culture medium is as follows: 10g/L of glucose, 25g/L of sodium glutamate, 10g/L of yeast extract, 20g/L of sodium chloride, 0.5g/L of magnesium sulfate and natural pH.
(2) Seed amplification culture: inoculating the activated seed culture solution cultured by shaking in the step (1) into an amplification culture medium according to the inoculation amount of 10% (volume ratio) for culturing, wherein a seed tank is a 10L seed amplification fermentation tank, the culture temperature is 28 ℃, the culture time is 48h, the shaking rotation speed of the shaking table is 200r/min, and the amplification culture medium in the seed tank is as follows: 40g/L glucose, 25g/L sodium glutamate, 10g/L yeast extract, 10g/L sodium chloride, 5g/L magnesium sulfate, 1g/L potassium dihydrogen phosphate, 0.5g/L calcium chloride and natural pH.
(3) And (3) fermentation bottle culture: inoculating the expanded seed culture solution cultured by shaking in the step (2) into a 50L fermentation tank filled with 30L of fermentation medium according to the inoculation amount of 10% (volume ratio), fermenting and culturing, wherein the culture temperature is 28 ℃, the culture time is 120h, the stirring speed is 220 r/min, the carbon source concentration in the fermentation broth is controlled to be 20g/L by feeding glucose in the fermentation process, the pH of the fermentation broth is controlled to be 7.2-7.8 by adding citric acid, and the fermentation medium is: 40g/L glucose, 4g/L yeast extract, 30g/L sodium glutamate, 5g/L sodium chloride, 1g/L monopotassium phosphate, 5g/L magnesium sulfate, 0.5g/L calcium chloride, 0.5g/L sodium bicarbonate, 8g/L sodium sulfate, 6g/L ammonium sulfate, 0.5g/L potassium chloride and natural pH.
(4) And (3) post-treatment: and (2) breaking the wall of fermentation liquor obtained by fermentation culture with alkaline protease, adding an extracting agent n-hexane for extraction, transferring a solid phase obtained by separation after extraction into an extraction container for repeated extraction, ending the extraction process until no oil exists in the extraction liquor, adding 200 ml of n-hexane during the first extraction, adding 150 ml of n-hexane each time, filtering and separating mixed oil after each extraction, and desolventizing to obtain the microbial oil.
(5) Gas chromatographic analysis: performing gas chromatography analysis on the microbial oil obtained in the step (4) to obtain the results shown in the table 3:
table 3 content of each fatty acid in DHA oil of example 4
Fatty acid composition Content (wt%)
14:0 5.27%
16:0 15.00%
18:0 0.41%
18:1 1.22%
18:2 2.43%
20:4n6 3.67%
20:5n3(EPA) 1.95%
22:5n6 15.00%
22:5n3 1.57%
22:6n3(DHA) 52.37%
In the DHA oil prepared by the mutant strain in the embodiment, the content of palmitic acid C16:0 is 15.0 wt%, the content of stearic acid C18:0 is 0.41 wt%, and the content of DHA reaches 52.37 wt%.
Example 5 production of docosahexaenoic acid Using Schizochytrium limacinum mutant strains
In this example, the method for producing docosahexaenoic acid by using the schizochytrium limacinum mutant obtained in example 1 is as follows:
(1) activating and culturing seeds: the schizochytrium limacinum mutant strain CABIO-A-2-II in example 1 is inoculated into an activation culture medium for culturing, the culture temperature is 28 ℃, the shaking table shaking speed is 200r/min, and the culture time is 48h, wherein the activation culture medium is as follows: 10g/L of glucose, 25g/L of sodium glutamate, 10g/L of yeast extract, 20g/L of sodium chloride, 0.5g/L of magnesium sulfate and natural pH.
(2) Seed amplification culture: inoculating the activated seed culture solution cultured by shaking in the step (1) into an amplification culture medium according to the inoculation amount of 10 percent (volume ratio) for culture, and sequentially inoculatingSelecting a volume of 100L, 1.7m3,12m3The seed tank is used for gradually expanding and culturing the seed liquid, the culture temperature is 28 ℃, the culture time is 48h, the shaking rotating speed of a shaking table is 200r/min, and the expanding culture medium in the seed tank is as follows: 40g/L glucose, 25g/L sodium glutamate, 10g/L yeast extract, 10g/L sodium chloride, 5g/L magnesium sulfate, 1g/L potassium dihydrogen phosphate, 0.5g/L calcium chloride and natural pH.
(3) And (3) fermentation bottle culture: inoculating the expanded seed culture solution cultured by shaking in the step (2) to a container containing 30m of the culture solution according to the inoculation amount of 10 percent (volume ratio)350m of fermentation Medium3Performing fermentation culture in a fermentation tank at the culture temperature of 28 ℃ for 120h at the stirring speed of 220 r/min, controlling the carbon source concentration in the fermentation broth to be 10g/L by feeding glucose in the fermentation process, and controlling the pH of the fermentation broth to be 6.8-7.2 by adding citric acid, wherein the fermentation culture medium is as follows: 40g/L glucose, 4g/L yeast extract, 30g/L sodium glutamate, 5g/L sodium chloride, 1g/L monopotassium phosphate, 5g/L magnesium sulfate, 0.5g/L calcium chloride, 0.5g/L sodium bicarbonate, 8g/L sodium sulfate, 6g/L ammonium sulfate, 0.5g/L potassium chloride and natural pH.
(4) And (3) post-treatment: and (2) breaking the wall of fermentation liquor obtained by fermentation culture with alkaline protease, adding an extracting agent n-hexane for extraction, transferring a solid phase obtained by separation after extraction into an extraction container for repeated extraction, ending the extraction process until no oil exists in the extraction liquor, adding 200 ml of n-hexane during the first extraction, adding 150 ml of n-hexane each time, filtering and separating mixed oil after each extraction, and desolventizing to obtain the microbial oil.
(5) Gas chromatographic analysis: performing gas chromatography analysis on the microbial oil obtained in the step (4) to obtain the results shown in the table 4:
table 4 content of each fatty acid in DHA oil of example 5
Figure BDA0002347036640000121
Figure BDA0002347036640000131
In the DHA oil prepared by the mutant strain in the embodiment, the content of palmitic acid C16:0 is 14.12 wt%, the content of stearic acid C18:0 is 0.40 wt%, and the content of DHA reaches 54.90 wt%. Example 6 production of docosahexaenoic acid Using Schizochytrium limacinum mutant strains
In this example, the method for producing docosahexaenoic acid by using the schizochytrium limacinum mutant obtained in example 1 is as follows:
(1) activating and culturing seeds: the schizochytrium limacinum mutant strain CABIO-A-2-II in example 1 is inoculated into an activation culture medium for culturing, the culture temperature is 28 ℃, the shaking table shaking speed is 200r/min, and the culture time is 48h, wherein the activation culture medium is as follows: 10g/L of glucose, 25g/L of sodium glutamate, 10g/L of yeast extract, 20g/L of sodium chloride, 0.5g/L of magnesium sulfate and natural pH.
(2) Seed amplification culture: inoculating the activated seed culture solution cultured by shaking in the step (1) into an amplification culture medium according to the inoculation amount of 10% (volume ratio) for culturing, and sequentially selecting 10L, 50L and 5m3,50m3The seed tank is used for gradually expanding and culturing the seed liquid, the culture temperature is 28 ℃, the culture time is 48 hours, the stirring is 200r/min, and the expanding culture medium in the seed tank is as follows: 40g/L glucose, 25g/L sodium glutamate, 10g/L yeast extract, 10g/L sodium chloride, 5g/L magnesium sulfate, 1g/L potassium dihydrogen phosphate, 0.5g/L calcium chloride and natural pH.
(3) And (3) fermentation bottle culture: inoculating the expanded seed culture solution cultured by shaking in the step (2) to a container with a volume of 130m according to an inoculation amount of 10 percent (volume ratio)3200m of fermentation medium3Fermenting and culturing in a fermentation bottle at the culture temperature of 28 ℃ for 120h under stirring at 220 r/min, wherein the carbon source concentration in the fermentation broth is controlled to be 5g/L by feeding glucose in the fermentation process, the pH of the fermentation broth is controlled to be 6.3-6.8 by adding citric acid, and the fermentation medium is: 40g/L glucose, 4g/L yeast extract, 30g/L sodium glutamate, 5g/L sodium chloride, 1g/L monopotassium phosphate, 5g/L magnesium sulfate, 0.5g/L calcium chloride, 0.5g/L sodium bicarbonate, 8g/L sodium sulfate, 6g/L ammonium sulfate, 0.5g/L potassium chloride and natural pH.
(4) And (3) post-treatment: and (2) breaking the wall of fermentation liquor obtained by fermentation culture with alkaline protease, adding an extracting agent n-hexane for extraction, transferring a solid phase obtained by separation after extraction into an extraction container for repeated extraction, ending the extraction process until no oil exists in the extraction liquor, adding 200 ml of n-hexane during the first extraction, adding 150 ml of n-hexane each time, filtering and separating mixed oil after each extraction, and desolventizing to obtain the microbial oil.
(5) Gas chromatographic analysis: the microbial oil obtained in step (4) was subjected to gas chromatography analysis, and the results shown in table 5 were obtained:
TABLE 5 content of fatty acids in DHA oil and fat in example 6
Fatty acid composition Content (wt%)
14:0 5.50%
16:0 12.50%
18:0 0.40%
18:1 1.90%
18:2 2.20%
20:4n6 3.01%
20:5n3(EPA) 1.50%
22:5n6 12.23%
22:5n3 1.25%
22:6n3(DHA) 57.08%
In the DHA oil prepared by the mutant strain in the embodiment, the content of palmitic acid C16:0 is 12.50 wt%, the content of stearic acid C18:0 is 0.40 wt%, and the content of DHA reaches 57.08 wt%.
In the above examples, it can be seen that the long-chain fatty acid in docosahexaenoic acid produced by the schizochytrium limacinum mutant strain CABIO-A-2-II is very obviously reduced, the fatty acid composition is optimized in A small range by optimizing the culture conditions, the minimum content of palmitic acid C16:0 can reach 12.50 wt%, the minimum content of stearic acid C18:0 can reach 0.40 wt%, and the maximum content of DHA can reach 57.08 wt%.
Although the invention has been described in detail hereinabove with respect to a general description and specific embodiments thereof, it will be apparent to those skilled in the art that modifications or improvements may be made thereto based on the invention. Accordingly, such modifications and improvements are intended to be within the scope of the invention as claimed.

Claims (10)

1. A Schizochytrium sp CABIO-A-2-II is characterized in that the preservation number of the Schizochytrium sp CABIO-A-2-II is CCTCCM 2019990.
2. A microbial preparation comprising the Schizochytrium sp CABIO-A-2-II mutant strain according to claim 1.
3. A method for producing docosahexaenoic acid oil, which comprises the following steps: fermenting the Schizochytrium sp (CABIO-A-2-II) strain of claim 1 or the microbial inoculum of claim 2, collecting the fermentation product, and separating and purifying.
4. Use of A mutant Schizochytrium sp (Schizochytrium sp) cab io-A-2-ii according to claim 1 or A microbial preparation according to claim 2 for the preparation of docosahexaenoic acid oil.
5. Use according to claim 4, wherein the docosahexaenoic acid oil/fat has a C16:0 content of less than 15.50 wt.%, preferably less than 15.00 wt.%, more preferably less than 14.12 wt.%, even more preferably less than 12.50 wt.%.
6. Use according to claim 5, wherein the docosahexaenoic acid oil/fat has a content of C18:0 of less than 0.51 wt.%, preferably less than 0.41 wt.%, more preferably less than 0.40 wt.%.
7. Use according to claim 5 or 6, wherein the sum of the contents of long-chain saturated fatty acids C16:0 and C18:0 in the docosahexaenoic acid oil is less than 16.01 wt.%, preferably less than 15.41 wt.%, more preferably less than 14.52 wt.%, even more preferably less than 12.90 wt.%.
8. Use according to any of claims 5 to 7, wherein the docosahexaenoic acid lipid has a DHA content higher than 50.40 wt%, preferably higher than 52.37 wt%, further preferably higher than 54.90 wt%, and even further preferably higher than 57.08 wt%.
9. Use of A mutant strain of Schizochytrium (Schizochytrium sp) CABIO-A-2-ii according to claim 1 or A bacterial agent according to claim 2 or A docosahexaenoic acid oil or fat as described in any one of claims 4 to 8 for the preparation of A food product, feed, cosmetic or pharmaceutical.
10. Microbial oil, characterized in that the content of docosahexaenoic acid oil in the microbial oil is at least 50%, and the content of long-chain saturated fatty acid C16:0 in the docosahexaenoic acid oil is less than 15.50 wt%, preferably less than 15.00 wt%, further preferably less than 14.12 wt%, and further preferably less than 12.50 wt%.
CN201911399018.2A 2019-12-30 2019-12-30 Schizochytrium limacinum mutant strain, and method and application thereof in preparation of docosahexaenoic acid grease Pending CN111235035A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201911399018.2A CN111235035A (en) 2019-12-30 2019-12-30 Schizochytrium limacinum mutant strain, and method and application thereof in preparation of docosahexaenoic acid grease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201911399018.2A CN111235035A (en) 2019-12-30 2019-12-30 Schizochytrium limacinum mutant strain, and method and application thereof in preparation of docosahexaenoic acid grease

Publications (1)

Publication Number Publication Date
CN111235035A true CN111235035A (en) 2020-06-05

Family

ID=70872247

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201911399018.2A Pending CN111235035A (en) 2019-12-30 2019-12-30 Schizochytrium limacinum mutant strain, and method and application thereof in preparation of docosahexaenoic acid grease

Country Status (1)

Country Link
CN (1) CN111235035A (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114164122A (en) * 2021-12-02 2022-03-11 嘉必优生物技术(武汉)股份有限公司 Schizochytrium limacinum for high yield of EPA and application thereof
CN114437947A (en) * 2022-04-08 2022-05-06 中国农业科学院北京畜牧兽医研究所 High-protein high-DHA schizochytrium limacinum trap strain and application thereof as feed additive
CN114525312A (en) * 2020-11-06 2022-05-24 嘉必优生物技术(武汉)股份有限公司 Method for producing DHA (docosahexaenoic acid) by using schizochytrium limacinum through fermentation
CN114686534A (en) * 2020-12-30 2022-07-01 嘉必优生物技术(武汉)股份有限公司 Preparation method of phospholipid type DHA

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11318484A (en) * 1998-05-14 1999-11-24 Sagami Chem Res Center Production of labeled highly-unsaturated fatty acid through microorganism
US20030100097A1 (en) * 1988-09-07 2003-05-29 Omegatech Inc. Process for the heterotrophic production of microbial products with high concentrations of omega-3 highly unsaturated fatty acids
WO2007074479A1 (en) * 2005-12-29 2007-07-05 Abl Biotechnologies Ltd Novel strain of schizochytrium limacinum useful in the production of lipids and extracellular polysaccharides and process thereof
CN102839129A (en) * 2011-06-23 2012-12-26 法国罗凯特兄弟公司 Fragmentation chytrid mutagenesis method and variant produced by fragmentation chytrid mutagenesis method
CN104450529A (en) * 2013-09-25 2015-03-25 郭星 Schizochytrium limacinum strain as well as mutagenesis method and application thereof
CN104995291A (en) * 2013-01-18 2015-10-21 协和发酵生化株式会社 Microorganisms producing docosahexaenoic acid and utilization thereof
CN105558305A (en) * 2015-12-10 2016-05-11 新奥科技发展有限公司 Schizochytrium limacinum and application thereof
CN107523504A (en) * 2016-06-21 2017-12-29 嘉必优生物技术(武汉)股份有限公司 Schizochytrium limacinum mutant strain
AU2018200956A1 (en) * 2000-01-19 2018-03-01 Dsm Ip Assets B.V. Solventless extraction process
KR101847551B1 (en) * 2016-11-04 2018-04-10 전북대학교산학협력단 Mutant microalgae Schizochytrium sp. SHG104 strain having high productivity of carotenoid-type antioxidant pigment and bio-oil containing DHA and uses thereof

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030100097A1 (en) * 1988-09-07 2003-05-29 Omegatech Inc. Process for the heterotrophic production of microbial products with high concentrations of omega-3 highly unsaturated fatty acids
JPH11318484A (en) * 1998-05-14 1999-11-24 Sagami Chem Res Center Production of labeled highly-unsaturated fatty acid through microorganism
AU2018200956A1 (en) * 2000-01-19 2018-03-01 Dsm Ip Assets B.V. Solventless extraction process
WO2007074479A1 (en) * 2005-12-29 2007-07-05 Abl Biotechnologies Ltd Novel strain of schizochytrium limacinum useful in the production of lipids and extracellular polysaccharides and process thereof
CN102839129A (en) * 2011-06-23 2012-12-26 法国罗凯特兄弟公司 Fragmentation chytrid mutagenesis method and variant produced by fragmentation chytrid mutagenesis method
CN106244576A (en) * 2011-06-23 2016-12-21 法国罗凯特兄弟公司 Schizochytrium limacinum method of mutagenesis and the variant of generation thereof
CN104995291A (en) * 2013-01-18 2015-10-21 协和发酵生化株式会社 Microorganisms producing docosahexaenoic acid and utilization thereof
CN104450529A (en) * 2013-09-25 2015-03-25 郭星 Schizochytrium limacinum strain as well as mutagenesis method and application thereof
CN107164238A (en) * 2013-09-25 2017-09-15 郭星 A kind of schizochytrium limacinum bacterial strain and its method of mutagenesis and application
CN105558305A (en) * 2015-12-10 2016-05-11 新奥科技发展有限公司 Schizochytrium limacinum and application thereof
CN107523504A (en) * 2016-06-21 2017-12-29 嘉必优生物技术(武汉)股份有限公司 Schizochytrium limacinum mutant strain
KR101847551B1 (en) * 2016-11-04 2018-04-10 전북대학교산학협력단 Mutant microalgae Schizochytrium sp. SHG104 strain having high productivity of carotenoid-type antioxidant pigment and bio-oil containing DHA and uses thereof

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BEN ZHAO等: "《Enhancement of Schizochytrium DHA synthesis by plasma mutagenesis aided with malonic acid and zeocin screening》", 《APPLIED MICROBIOLOGY AND BIOTECHNOLOGY》 *
DENIZ SAHIN等: "《Enhancement of docosahexaenoic acid (DHA) production from Schizochytrium》", 《AMB EXPRESS.》 *
FANGZHONG WANG等: "《Metabolic engineering to enhance biosynthesis of both docosahexaenoic acid and odd‑chain fatty acids in Schizochytrium sp.S31》", 《BIOTECHNOL BIOFUELS》 *
XIU-HONG YUE等: "《Lipid Distribution Pattern and Transcriptomic Insights Revealed the Potential Mechanism of Docosahexaenoic Acid Traffics in Schizochytrium sp. A‑2》", 《J. AGRIC. FOOD CHEM.》 *
李慧玲等: "《诱变选育高产DHA裂殖壶菌突变株》", 《食品科技》 *
袁军等: "《常压室温等离子体(ARTP)诱变快速选育高产DHA的裂殖壶菌突变株》", 《生物技术通报》 *
赵犇等: "《EMS-ARTP复合诱变选育高产DHA裂殖壶菌》", 《食品与机械》 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114525312A (en) * 2020-11-06 2022-05-24 嘉必优生物技术(武汉)股份有限公司 Method for producing DHA (docosahexaenoic acid) by using schizochytrium limacinum through fermentation
CN114686534A (en) * 2020-12-30 2022-07-01 嘉必优生物技术(武汉)股份有限公司 Preparation method of phospholipid type DHA
CN114164122A (en) * 2021-12-02 2022-03-11 嘉必优生物技术(武汉)股份有限公司 Schizochytrium limacinum for high yield of EPA and application thereof
CN114164122B (en) * 2021-12-02 2023-06-20 嘉必优生物技术(武汉)股份有限公司 Schizochytrium limacinum with high EPA yield and application thereof
CN114437947A (en) * 2022-04-08 2022-05-06 中国农业科学院北京畜牧兽医研究所 High-protein high-DHA schizochytrium limacinum trap strain and application thereof as feed additive

Similar Documents

Publication Publication Date Title
CN111235035A (en) Schizochytrium limacinum mutant strain, and method and application thereof in preparation of docosahexaenoic acid grease
JP5940194B2 (en) Method for producing high levels of DHA in microalgae using modified amounts of chloride and potassium
AU2016399463B2 (en) Omega-7 fatty acid composition, methods of cultivation of Tribonema for production of composition and application of composition
CN108004149B (en) Marine protist and method for producing high value-added lipid product by fermenting marine protist
JP5942197B2 (en) Novel microorganism having high squalene production ability and method for producing squalene using the same
US6410282B1 (en) Method for enhancing levels of polyunsaturated fatty acids in thraustochytrid fungi
WO2017219987A1 (en) Schizochytrium limacinum mutant strain
CN1986822A (en) Crypthecodinium connii fermenting process for producing docosahexaenoic acid grease
CN113308387B (en) Bacterial strain for co-production of unsaturated fatty acid and carotenoid and application thereof
CN103602591B (en) A kind of schizochytrium limacinum and the method for the production of docosahexaenoic acid grease
CN108004277B (en) Method for preparing linoleic acid by using bacillus megatherium
EP3839041A1 (en) Semi-continuous culture methods
CN103882072B (en) A kind of method utilizing schizochytrium limacinum to produce docosahexenoic acid
CN114164122B (en) Schizochytrium limacinum with high EPA yield and application thereof
CN116355816A (en) Microorganism of fermented samara oil seed and blood lipid reducing composition thereof
AU2004225662A1 (en) A method of enhancing levels of polyunsaturated fatty acids in thraustochytrid protists
CN112481133A (en) Culture medium for separating thraustochytrid and purification method thereof
JP4813770B2 (en) Animal plankton feed and zooplankton culture method using the same
CN115109803A (en) Method for increasing yield of polyunsaturated fatty acids in microorganisms and method for preparing microbial oil
EP1276891B1 (en) A method for enhancing levels of polyunsaturated fatty acids in thraustochytrids
CN114958932B (en) Application of regulating factor in improving polyunsaturated fatty acid content of oleaginous microorganism and preparation method of microbial oil
CN114807256B (en) Application of sodium alginate and ferulic acid in improving EPA yield of oleaginous microorganisms and preparation method of microbial grease
JP2004298123A (en) Method for treating yeast residue and animal feed obtained by the method
CN114456947A (en) Fine cordyceps strain and artificial culture method thereof
CN108949575A (en) A kind of hidden dinoflagellate of high DHA content and its application

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20200605